Obinutuzumab inj
Products billed under this code include Gazyva.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Gazyva.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Gazyva | Genentech, Inc. | 50242-0070-01 | 100 | $8,503.90 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $85.039 | +$0.576 | 10 MG | Obinutuzumab inj | v1, posted September 17, 2026 |
| 3Q26 | $84.463 | +$2.657 | 10 MG | Obinutuzumab inj | v1, posted September 15, 2026 |
| 2Q26 | $81.806 | +$0.181 | 10 MG | Obinutuzumab inj | v1, posted September 15, 2026 |
| 1Q26 | $81.625 | +$2.629 | 10 MG | Obinutuzumab inj | v1, posted September 15, 2026 |
| 4Q25 | $78.996 | +$0.535 | 10 MG | Obinutuzumab inj | v1, posted September 8, 2026 |
| 3Q25 | $78.461 | +$3.249 | 10 MG | Obinutuzumab inj | v1, posted March 10, 2026 |
| 2Q25 | $75.212 | +$0.385 | 10 MG | Obinutuzumab inj | v1, posted March 10, 2026 |
| 1Q25 | $74.827 | +$0.239 | 10 MG | Obinutuzumab inj | v1, posted December 19, 2025 |
| 4Q24 | $74.588 | +$0.438 | 10 MG | Obinutuzumab inj | v1, posted June 11, 2025 |
| 3Q24 | $74.15 | +$3.934 | 10 MG | Obinutuzumab inj | v1, posted June 11, 2025 |
| 2Q24 | $70.216 | −$0.126 | 10 MG | Obinutuzumab inj | v1, posted March 11, 2025 |
| 1Q24 | $70.342 | +$0.056 | 10 MG | Obinutuzumab inj | v1, posted December 19, 2024 |
| 4Q23 | $70.286 | −$0.26 | 10 MG | Obinutuzumab inj | v1, posted October 10, 2024 |
| 3Q23 | $70.546 | +$3.634 | 10 MG | Obinutuzumab inj | v1, posted June 5, 2024 |
| 2Q23 | $66.912 | −$0.036 | 10 MG | Obinutuzumab inj | v1, posted February 23, 2024 |
| 1Q23 | $66.948 | −$0.406 | 10 MG | Obinutuzumab inj | v1, posted December 6, 2023 |
| 4Q22 | $67.354 | +$1.349 | 10 MG | Obinutuzumab inj | v1, posted June 22, 2023 |
| 3Q22 | $66.005 | +$2.187 | 10 MG | Obinutuzumab inj | v1, posted June 9, 2023 |
| 2Q22 | $63.818 | −$0.29 | 10 MG | Obinutuzumab inj | v1, posted December 14, 2022 |
| 1Q22 | $64.108 | −$0.428 | 10 MG | Obinutuzumab inj | v1, posted June 8, 2022 |
| 4Q21 | $64.536 | +$0.12 | 10 MG | Obinutuzumab inj | v1, posted June 2, 2022 |
| 3Q21 | $64.416 | +$1.332 | 10 MG | Obinutuzumab inj | v1, posted June 2, 2022 |
| 2Q21 | $63.084 | −$0.459 | 10 MG | Obinutuzumab inj | v1, posted March 1, 2022 |
| 1Q21 | $63.543 | – | 10 MG | Obinutuzumab inj | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.